Zion Pharma Announces Global Agreement with Roche to Develop and Commercialize a Blood Brain Barrier Penetrant Oral HER2 Tyrosine Kinase Inhibitor

Zion Pharma Limited a Chinese biotechnology company focused on the development of brainpenetrable compounds today announced that Roche has acquired the global rights to Zions lead program ZNA1041. ZNA1041 is an orally administered selective tyrosine kinase inhibitor targeting the Human Epidermal Growth Factor Receptor 2 HER2.

Related Keywords

Ding Zhou ,Hebei ,China ,Hong Kong ,Shanghai ,Suzhou ,Jiangsu ,Chinese ,Zion Pharma ,James Sabry ,Zack Cheng ,Corporate Development ,Founder Of Zion Pharma ,Pharma Limited ,Human Epidermal Growth Factor Receptor ,Zion Pharma Limited ,Global Head ,American Society ,Clinical Oncology Annual Meeting ,Media Contact ,Zion Pharma Limited Chinese Biotechnology Brainpenetrable Compounds Roche Zna1041 Her2 Her2positive Metastatic Breast Cancer Zack Cheng Dr Ding Zhou James Sabry Human Epidermal Growth Factor Receptor 2 Ataxia Telangiectasia Mutated Kirsten Rat Sarcoma Kras G12d Smarca2 Blood Brain Barrier Penetrant ,